TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an announcement.
CanSino Biologics Inc. has initiated a Phase I clinical trial in Indonesia for its inhaled tuberculosis booster vaccine, marking the completion of the first patient enrollment. This innovative vaccine aims to enhance the efficacy of the existing Bacillus Calmette-Guerin vaccine by stimulating a stronger immune response in the lungs, potentially controlling latent infections and preventing new ones. The trial will assess the safety and immunogenicity of the vaccine in adults, leveraging the company’s expertise in inhalation technology developed for COVID-19 vaccines.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biopharmaceutical company based in China, specializing in the development of vaccines. The company focuses on innovative vaccine solutions, including those for tuberculosis and COVID-19, with a strong emphasis on inhalation-based delivery systems.
Average Trading Volume: 1,436,574
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.39B
See more data about 6185 stock on TipRanks’ Stock Analysis page.